Welcome to our dedicated page for Cell Medx news (Ticker: CMXC), a resource for investors and traders seeking the latest updates and insights on Cell Medx stock.
StimCell Energetics Inc. (OTC Pink: CMXC) delivers innovative cellular energy solutions targeting wellness and chronic health management through its proprietary eBalance® Technology. This comprehensive news hub provides investors and industry observers with essential updates on the company's therapeutic developments, strategic partnerships, and regulatory progress.
Access real-time updates on clinical trial advancements, product commercialization efforts, and financial disclosures. Our curated news feed covers material developments including technology patents, research collaborations, and market expansion initiatives within the cellular energetics sector.
Key content categories include scientific breakthroughs, executive leadership changes, and operational milestones. The platform serves as a centralized resource for understanding StimCell's position in the competitive biotech landscape while maintaining strict compliance with financial disclosure standards.
Bookmark this page for direct access to verified corporate communications and analysis-free reporting on CMXC's progress in bridging medical innovation with wellness applications. Monitor the company's trajectory in transforming cellular health management through energy optimization technologies.
StimCell Energetics Inc. (OTC PINK:CMXC), formerly Cell MedX Corp., announced major corporate changes including a name change and a 1:15 reverse stock split. The company's authorized capital decreased from 7.5 billion to 500 million shares, with outstanding shares reducing from 297,236,373 to approximately 19,815,758. Starting November 5, 2024, the stock will trade as 'CMXCD' for 20 business days before seeking a new symbol. The biotech company, focusing on cellular energy for anti-aging and wellness, also launched a new website at www.StimCell.com.
